Genzyme Summary Essay

Genzyme was founded in 1981, Sanofi purchased the lodge in 2011. They went public in 1986, bringing up 27 million dollars. Genzyme seize onet as a start up Company by scientists studying genetically inherited enzyme diseases. Their dodging didnt focalisation on the smash hit medicates like other biotechnology companies only drugs for rare diseases. To developing a drug, it takes 10-14 eld at the cost of around 800 million. unless the blockbuster drugs had 1 billion dollars receipts. Genzyme has original several honor awards like content medal of technology.The food and drug administration established in 1983 the Orphane drug act giving seven age foodstuff exclusivity to developers of drugs for rare diseases. This gave Genzyme big gain when it comes to clinical trials, advertising and gross sales, it does not requires a lot. Their first success was the Ceredase drug- to treat the Gauchers disease. It was sold to over 4000 patients, with annual revenue of 800 million dollars. They had different way of manufacturing and sales compare to other companies. They did not do licensing to large pharmaceutical political party. Genzyme was the worlds third largest biotech bon ton in 2006 only profiting of rare diseases. contemplation of the case* Avoided blockbuster grocery store and penny-pinching managementGood strategic to focus on a niche market instead of the blockbuster market. The degree of b assay rivalry and entry barriers was low. Henri Termeer took a risk in moving to a start up company but with his invite and expertise, the company went stronger and independent.* First ones to market and the exclusivityGenzyme entered a small, untapped market. Being the first biotech company that focus on rare diseases and having the market exclusivity made them leading biotech company. They had the ability to invest almost all customers. They had big wages when is comes to clinical trials, restrictions, FDA and small numbers of attempt patients requi red.